Biotech firm Intradigm has tacked an additional $2.9 million onto its second round of funding, bringing its total to $21.4 million. The new money will be used to advance its RNA interference-based line of therapeutics used to treat cancer.
The Palo Alto, Calif.-based company says it distinguishes itself from others pursuing RNA interference strategies by also offering technology to deliver treatment to very specific locations within the body.
Astellas Venture Management led this most recent tranche, which also included Lilly Ventures. Roche Venture Fund, MP Healthcare Venture Management, Alta Partners, Frazier Healthcare Ventures, MediBic Alliance Technology Fund and Novartis Venture Fund also participated in the second round.
